Business, energy, technology, markets and global industry news from Business News Today

Novo Nordisk

PharmaDeviceNews Novo Nordisk
Novo Nordisk closes $5.2bn acquisition of Akero Therapeutics and its MASH pipeline.
Pharma & Biotech

Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care

Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.

Read More
Novo Nordisk is seeking approval for 7.2 mg Wegovy (semaglutide) from the FDA .
Pharma & Biotech

Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?

Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.

Read More